Lenalidomide in non-deletion 5q lower-risk myelodysplastic syndromes: a glass quarter full or three quarters empty?

Leuk Lymphoma. 2018 Sep;59(9):2015-2017. doi: 10.1080/10428194.2018.1430797. Epub 2018 Feb 7.

Authors

Rory M Shallis¹, Amer M Zeidan^{1

2}

Affiliations

¹ a Department of Internal Medicine School of Medicine , Yale University , New Haven , USA.
² b Cancer Outcomes, Public Policy, and Effectiveness Research (COPPER) Center, Yale University , New Haven , USA.

PMID: 29411698
DOI: 10.1080/10428194.2018.1430797

No abstract available

Publication types

Comment

MeSH terms

Abnormalities, Multiple
Chromosome Deletion*
Chromosomes, Human, Pair 2
Humans
Lenalidomide*
Myelodysplastic Syndromes / genetics

Substances

Lenalidomide